Cost of de novo acute myeloid leukemia induction therapy in adults: Analysis of EORTC-GIMEMA AML10 and FLANG regimens

M. Clavio, S. Quintino, B. Masoudi, S. Carrara, R. Cerri, I. Pierri, L. Canepa, M. Miglino, P. Muner, E. Damasio, M. Gobbi

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Since the social and financial impact of AML therapy is becoming more and more relevant we analyzed the cost of induction therapy of two different regimens. The first one is part of the widely employed EORTC-GIMEMA AML-10 and consists of ten days of therapy. The second (FLANG) is a short (three day), Fludarabine, Ara-C, mitoxantrone and G-CSF containing regimen. We first retrospectively analyzed the outcome of 77 consecutive AML patients with comparable clinical and haematological features receiving FLANG (25) or AML-10 (52), between June 1993 and October 1999, and observed equivalent CR rate, as well as DFS and overall survival duration. We then selected 9 non pretreated patients per group who reached CR after one course of therapy. Patients treated with FLANG had a statistically significant earlier platelet recovery compared to those treated with AML-10, fewer days of intravenous antibiotic therapy (14 / 22, respectively, p <0.05), and a shorter hospitalization period (22 / 33 days, p <0.01). FLANG was significantly more expensive than AML 10 as far as the cost of antiblastic drugs (p <0.01) and G-CSF support (p <0.05) are concerned. On the contrary, the expense for antiemetic drugs (p <0.01) and the cost of personnel and other services ($ 5,906 / $ 3,970, p <0.05) were higher for AML-10 than for FLANG. Overall, the average costs of FLANG and AML10 were $9,269 and $12,424 respectively (p <0.05; difference = -25%). Our study seems to indicate that, compared to AML-10, FLANG induction is as effective, less expensive and it allows for a decrease in the length of hospitalization and thus for better exploitation of the financial resources of Hematology-Oncology departments.

Original languageEnglish
Pages (from-to)165-173
Number of pages9
JournalJournal of Experimental and Clinical Cancer Research
Volume20
Issue number2
Publication statusPublished - 2001

Fingerprint

Acute Myeloid Leukemia
Costs and Cost Analysis
Granulocyte Colony-Stimulating Factor
Hospitalization
Therapeutics
Mitoxantrone
Drug Costs
Antiemetics
Cytarabine
Hematology
Blood Platelets
Anti-Bacterial Agents
Survival

Keywords

  • AML induction therapy
  • AML-10
  • Cost
  • FLANG
  • Fludarabine

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Cost of de novo acute myeloid leukemia induction therapy in adults : Analysis of EORTC-GIMEMA AML10 and FLANG regimens. / Clavio, M.; Quintino, S.; Masoudi, B.; Carrara, S.; Cerri, R.; Pierri, I.; Canepa, L.; Miglino, M.; Muner, P.; Damasio, E.; Gobbi, M.

In: Journal of Experimental and Clinical Cancer Research, Vol. 20, No. 2, 2001, p. 165-173.

Research output: Contribution to journalArticle

Clavio, M, Quintino, S, Masoudi, B, Carrara, S, Cerri, R, Pierri, I, Canepa, L, Miglino, M, Muner, P, Damasio, E & Gobbi, M 2001, 'Cost of de novo acute myeloid leukemia induction therapy in adults: Analysis of EORTC-GIMEMA AML10 and FLANG regimens', Journal of Experimental and Clinical Cancer Research, vol. 20, no. 2, pp. 165-173.
Clavio, M. ; Quintino, S. ; Masoudi, B. ; Carrara, S. ; Cerri, R. ; Pierri, I. ; Canepa, L. ; Miglino, M. ; Muner, P. ; Damasio, E. ; Gobbi, M. / Cost of de novo acute myeloid leukemia induction therapy in adults : Analysis of EORTC-GIMEMA AML10 and FLANG regimens. In: Journal of Experimental and Clinical Cancer Research. 2001 ; Vol. 20, No. 2. pp. 165-173.
@article{bf0cea184c9e423a8e4cea3e9e2881f2,
title = "Cost of de novo acute myeloid leukemia induction therapy in adults: Analysis of EORTC-GIMEMA AML10 and FLANG regimens",
abstract = "Since the social and financial impact of AML therapy is becoming more and more relevant we analyzed the cost of induction therapy of two different regimens. The first one is part of the widely employed EORTC-GIMEMA AML-10 and consists of ten days of therapy. The second (FLANG) is a short (three day), Fludarabine, Ara-C, mitoxantrone and G-CSF containing regimen. We first retrospectively analyzed the outcome of 77 consecutive AML patients with comparable clinical and haematological features receiving FLANG (25) or AML-10 (52), between June 1993 and October 1999, and observed equivalent CR rate, as well as DFS and overall survival duration. We then selected 9 non pretreated patients per group who reached CR after one course of therapy. Patients treated with FLANG had a statistically significant earlier platelet recovery compared to those treated with AML-10, fewer days of intravenous antibiotic therapy (14 / 22, respectively, p <0.05), and a shorter hospitalization period (22 / 33 days, p <0.01). FLANG was significantly more expensive than AML 10 as far as the cost of antiblastic drugs (p <0.01) and G-CSF support (p <0.05) are concerned. On the contrary, the expense for antiemetic drugs (p <0.01) and the cost of personnel and other services ($ 5,906 / $ 3,970, p <0.05) were higher for AML-10 than for FLANG. Overall, the average costs of FLANG and AML10 were $9,269 and $12,424 respectively (p <0.05; difference = -25{\%}). Our study seems to indicate that, compared to AML-10, FLANG induction is as effective, less expensive and it allows for a decrease in the length of hospitalization and thus for better exploitation of the financial resources of Hematology-Oncology departments.",
keywords = "AML induction therapy, AML-10, Cost, FLANG, Fludarabine",
author = "M. Clavio and S. Quintino and B. Masoudi and S. Carrara and R. Cerri and I. Pierri and L. Canepa and M. Miglino and P. Muner and E. Damasio and M. Gobbi",
year = "2001",
language = "English",
volume = "20",
pages = "165--173",
journal = "Journal of Experimental and Clinical Cancer Research",
issn = "0392-9078",
publisher = "BioMed Central Ltd.",
number = "2",

}

TY - JOUR

T1 - Cost of de novo acute myeloid leukemia induction therapy in adults

T2 - Analysis of EORTC-GIMEMA AML10 and FLANG regimens

AU - Clavio, M.

AU - Quintino, S.

AU - Masoudi, B.

AU - Carrara, S.

AU - Cerri, R.

AU - Pierri, I.

AU - Canepa, L.

AU - Miglino, M.

AU - Muner, P.

AU - Damasio, E.

AU - Gobbi, M.

PY - 2001

Y1 - 2001

N2 - Since the social and financial impact of AML therapy is becoming more and more relevant we analyzed the cost of induction therapy of two different regimens. The first one is part of the widely employed EORTC-GIMEMA AML-10 and consists of ten days of therapy. The second (FLANG) is a short (three day), Fludarabine, Ara-C, mitoxantrone and G-CSF containing regimen. We first retrospectively analyzed the outcome of 77 consecutive AML patients with comparable clinical and haematological features receiving FLANG (25) or AML-10 (52), between June 1993 and October 1999, and observed equivalent CR rate, as well as DFS and overall survival duration. We then selected 9 non pretreated patients per group who reached CR after one course of therapy. Patients treated with FLANG had a statistically significant earlier platelet recovery compared to those treated with AML-10, fewer days of intravenous antibiotic therapy (14 / 22, respectively, p <0.05), and a shorter hospitalization period (22 / 33 days, p <0.01). FLANG was significantly more expensive than AML 10 as far as the cost of antiblastic drugs (p <0.01) and G-CSF support (p <0.05) are concerned. On the contrary, the expense for antiemetic drugs (p <0.01) and the cost of personnel and other services ($ 5,906 / $ 3,970, p <0.05) were higher for AML-10 than for FLANG. Overall, the average costs of FLANG and AML10 were $9,269 and $12,424 respectively (p <0.05; difference = -25%). Our study seems to indicate that, compared to AML-10, FLANG induction is as effective, less expensive and it allows for a decrease in the length of hospitalization and thus for better exploitation of the financial resources of Hematology-Oncology departments.

AB - Since the social and financial impact of AML therapy is becoming more and more relevant we analyzed the cost of induction therapy of two different regimens. The first one is part of the widely employed EORTC-GIMEMA AML-10 and consists of ten days of therapy. The second (FLANG) is a short (three day), Fludarabine, Ara-C, mitoxantrone and G-CSF containing regimen. We first retrospectively analyzed the outcome of 77 consecutive AML patients with comparable clinical and haematological features receiving FLANG (25) or AML-10 (52), between June 1993 and October 1999, and observed equivalent CR rate, as well as DFS and overall survival duration. We then selected 9 non pretreated patients per group who reached CR after one course of therapy. Patients treated with FLANG had a statistically significant earlier platelet recovery compared to those treated with AML-10, fewer days of intravenous antibiotic therapy (14 / 22, respectively, p <0.05), and a shorter hospitalization period (22 / 33 days, p <0.01). FLANG was significantly more expensive than AML 10 as far as the cost of antiblastic drugs (p <0.01) and G-CSF support (p <0.05) are concerned. On the contrary, the expense for antiemetic drugs (p <0.01) and the cost of personnel and other services ($ 5,906 / $ 3,970, p <0.05) were higher for AML-10 than for FLANG. Overall, the average costs of FLANG and AML10 were $9,269 and $12,424 respectively (p <0.05; difference = -25%). Our study seems to indicate that, compared to AML-10, FLANG induction is as effective, less expensive and it allows for a decrease in the length of hospitalization and thus for better exploitation of the financial resources of Hematology-Oncology departments.

KW - AML induction therapy

KW - AML-10

KW - Cost

KW - FLANG

KW - Fludarabine

UR - http://www.scopus.com/inward/record.url?scp=0034934467&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034934467&partnerID=8YFLogxK

M3 - Article

C2 - 11484970

AN - SCOPUS:0034934467

VL - 20

SP - 165

EP - 173

JO - Journal of Experimental and Clinical Cancer Research

JF - Journal of Experimental and Clinical Cancer Research

SN - 0392-9078

IS - 2

ER -